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http://dx.doi.org/10.1016/j.stemcr.2017.04.010SUMMARYAlthough it is important to clarify the pathogenic functions of T cells in human samples, their examination is often limited due to
difficulty in obtaining sufficient numbers of dendritic cells (DCs), used as antigen-presenting cells, especially in autoimmune diseases.
We describe the generation of DCs from induced pluripotent stem cells derived from T cells (T-iPSCs). We reprogrammed CD4+ T cell
clones from a patient with Sjo¨gren’s syndrome (SS) into iPSCs, which were differentiated into DCs (T-iPS-DCs). T-iPS-DCs had dendritic
cell-like morphology, and expressed CD11c, HLA-DR, CD80, CD86, and also BDCA-3. Compared with monocyte-derived DCs, the capa-
city for antigen processingwas similar, and T-iPS-DCs induced the proliferative response of autoreactive CD4+ Tcells. Moreover, we could
evaluate T cell functions of the patient with SS. In conclusion, we obtained adequate numbers of DCs from T-iPSCs, which could be used
to characterize pathogenic T cells in autoimmune diseases such as SS.INTRODUCTION
Sjo¨gren’s syndrome (SS) is an autoimmune disease char-
acterized by infiltration of lymphocytes into lacrimal
and salivary glands (Fox and Stern, 2002). Immunohisto-
chemical studies have shown that most infiltrating
lymphocytes are CD4+ abT cells. With respect to the
cytokine profile, overexpression of interferon gamma
(IFN-g) has been described in salivary glands of SS, and
CD4+ T cells, which produce IFN-g, activate salivary
gland epithelial cells (Kawakami et al., 2012; Iizuka
et al., 2012). Moreover, a high proportion of IFN-g-pro-
ducing CD4+ T cells is present among peripheral blood
mononuclear cells (PBMCs), suggesting that they play
an important role in the pathogenesis of SS (Koarada
et al., 2006). Although many reports support the involve-
ment of IFN-g-producing CD4+ T cells in SS, there are
only a few reports that provide precise analysis of
CD4+ T cells, establishing monoclonal T cell lines from
patients with SS.
Dendritic cells (DCs), used as antigen-presenting cells
(APCs) in the analysis of CD4+ T cells, usually differentiate
from monocytes in vitro. However, monocytes cannot be
propagated, and obtaining sufficient number of these cells
is not feasible since it requires an abundant amount ofStem Cell
This is an open access article under the Cblood. Thus, versatile methods for obtaining sufficient
numbers of APCs are needed.
Induced pluripotent stem cells (iPSCs) are generated
from various cell types upon enforced expression of
transcription factors, such as Oct4, Klf4, Sox2, and c-Myc
(Takahashi et al., 2007). T cells could also convert into
iPSCs (T-iPSCs), retaining rearranged TCR genes from the
original T cell, and then re-differentiate into functional
T cells (Nishimura et al., 2013; Vizcardo et al., 2013; Ando
et al., 2015). Recently, differentiation of DCs from human
iPSCs (iPS-DCs) derived from fibroblasts has been reported
(Choi et al., 2009; Senju et al., 2011). There is no informa-
tion, however, whether T-iPSCs, especially from patients
with autoimmune diseases such as SS, could differentiate
into functional DCs. For this reason, we tried to establish
DCs from T-iPSCs via Sacs. This approach would be criti-
cally useful not only as a less invasive approach for patients
but also due to the lower cost and less effort than other
methods. Thus, it could replace conventional methods
in which DCs are prepared from only a few monocytes
or from iPS-DCs obtained from non-PBMCs such as
fibroblasts.
In this study, we established DCs from T-iPSCs of
patients with SS. This could be used in the functional ex-
amination of pathogenic T cells without any concernReports j Vol. 8 j 1155–1163 j May 9, 2017 j ª 2017 The Author(s). 1155
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
regarding the preparation of monocytes or the back-
ground of donors.RESULTS
Generation of T-iPSCs from T Cell Clones
First, to establish CD4+ T cell clones, we isolated single
CD4+ T cells from PBMCs of a patient with primary SS.
The patient had not been treated, and satisfied the Japanese
Ministry of Health criteria for the diagnosis of SS (Fujibaya-
shi et al., 2004).
From 384 wells of a single CD4+ cell, we obtained 32
clones. To rule out the possibility that clones were derived
from feeder cells (irradiated allogenic PBMCs), we checked
the haplotype of HLA-DRB1 and confirmed they were
identical to that of the patient with SS. Since IFN-g pro-
ducing CD4+ Tcells are thought to be involved in the path-
ogenesis of SS (Singh and Cohen, 2012), we checked IFN-g
production from the clones and selected four clones, SS1-9,
SS3-6, SS4-6, and SS4-7, which produced more IFN-g than
the others (Figure S1A). These clones were all CD4+
T cells and did not express CD8 molecules (Figure S1B).
Moreover, we confirmed their monoclonality from the
TCR Vb repertoire (Figures S1C and S1D).
Next, we transduced these clones with reprogramming
factors via Sendai virus vectors, and developed iPSCs
(T-iPSCs) (Nishimura et al., 2013). We obtained 12 colonies
from the above four T cell clones, and of these, four
colonies could be stably cultured without feeder cells
(TkSST1-2, TkSST1-3, TkSST1-4 from SS3-6, and TkSST2-2
from SS4-6). These T-iPSCs had embryonic stem cell
(ESC)-like morphology (Figure S2A, and data not shown)
and overexpressed pluripotency markers of SSEA4, Oct4,
and Nanog (Figure S2B, and data not shown). They
were cultured on C3H10T1/2 cells and checked on
CD34+CD43+ early hematopoietic progenitor cells, which
had comparable capacity to differentiate into myeloid cells
(Vodyanik et al., 2006) (Figure S2C). Since the highest pro-
portion of CD34+CD43+ cells were TkSST2-2 compared
with the other three T-iPSCs, they were selected for the
following experiments. The usage of TCR Vb and the
sequence of the CDR3 region in TkSST2-2 were consistent
with those of the original T cell clone (SS4-6) (Figures
S1D, S2D, and S2E), demonstrating that T-iPSCswere devel-
oped from the above-mentioned single CD4+ T cell clone.Differentiation of T-iPSCs into DCs
We induced the differentiation of T-iPSCs into DCs (T-iPS-
DCs) (Figure 1A). T-iPSCs were cultured on C3H10T1/2
cells to differentiate into hematopoietic cells through
TiPS-Sacs (Figure 1B). TiPS-Sacs consisted of a morphologi-
cally distinct external layer that enveloped thousands of1156 Stem Cell Reports j Vol. 8 j 1155–1163 j May 9, 2017spherical cells. TiPS-Sacs were dissociated into single cells
and cultured in the presence of GM-CSF and M-CSF
without feeder cells (pre-immature cells of T-iPS-DCs
[preDCs]) (Figure 1C). To acquire more CD11c+ mature
DCs, we evaluated the culture period (Figure S3A). As a
culture period of 14 days with GM-SCF andM-SCF induced
the greatest numbers of CD11c+ DCs constantly, we used
that for the following protocol (Figure S3B). The expression
of CD117, also known as c-kit, in the cells cultured with
these cytokines for 14 days had already disappeared, and
the cells did not fit the phenotype of precursor DCs (Breton
et al., 2015) (Figures S3C and S3D). We added GM-CSF and
interleukin-4 (IL-4) to generate immature T-iPS-DCs (Fig-
ure 1D), and finally, OK432 was added (Figure 1E). Mature
T-iPS-DCs, and mo-DCs by way of comparison, were
analyzed with May-Grunwald-Giemsa staining and found
to have DC-like morphology (Figure 1F). Thus, mature
DCs were assumed to be established from T-iPSCs.
Characterization of T-iPS-DCs
We examined cell surfacemarkers specific for DCs. The cells
within TiPS-Sacs expressed CD34, CD43 (hematopoietic
cells), and CD31 (endothelial cells) (Figure 2A). This result
suggests that the cells weremultipotent hematopoietic pro-
genitors. InTiPS-Sacs,HLA-DRwasnotdetected,butCD11b,
CD11c, and HLA-ABC were slightly expressed. In preDCs,
CD11b andCD45 expressed higher andCD14was detected,
which is related to myeloid precursor cells (Figure 2B). In
addition, CD80, CD83, and CD86 were slightly expressed
but not HLA-DR. When advancing the step of immature
T-iPS-DCs, not only co-stimulatory molecules (CD40,
CD80, and CD86) but also HLA-DR expression were clearly
observed (Figures 2C and S4A). Mature T-iPS-DCs expressed
ahigher levelofCD40 than immatureT-iPS-DCs (Figure2D).
As for theproportionofCD11c+ cells,mature and immature
T-iPS-DCs were significantly higher than preDCs and TiPS-
Sacs (Figure 2E). To further evaluate the phenotype of
T-iPS-DCs, we checked the expression of both BDCA-1 and
BDCA-3 (Figure 2F). Intriguingly, T-iPS-DCs expressed
BDCA-3 but had little BDCA-1.
We also analyzed the chemokines and transcription
factors specific for DCs. Although CCL17, CCL13, and
MMP12 were rarely expressed in TiPS-Sacs and preDCs,
they were significantly upregulated in the mature T-iPS-
DCs and mo-DC (Figure 3A). The expression of MMP12
was significantly higher on mature T-iPS-DCs than imma-
ture DCs. PU.1, which is higher in myeloid DCs (mDC)
compared with plasmacytoid DCs (pDC), was also detected
inmature T-iPS-DCs (Nutt et al., 2005). On the other hand,
pre-T cell receptor a expression, expressed in pDCs, but not
inmDCs, was not detected (Figure 3B). It has been reported
that BDCA-3+ DCs expressed the signature marker of
CLEC9A (Haniffa et al., 2012); T-iPS-DCs expressed it
Figure 1. Differentiation of T-iPS-DCs
from T-iPSCs
(A) Schematic illustration of differentiation
of T-iPSCs into T-iPS-DCs.
(B–E) Phase-contrast images of TiPS-Sacs
on day 13 on C3H10T1/2 feeder cells (B),
pre-immature cells of T-iPS-DCs (C), imma-
ture T-iPS-DCs (D), and mature T-iPS-DCs
(E). Original magnification (B) 2003, bars
represent 20 mm; (C–E) 4003, bars repre-
sent 50 mm. Data are representative of ten
cultured samples.
(F) May-Grunwald-Giemsa staining of mature
T-iPS-DCs and mo-DCs. Original magnifica-
tion 4003, bars represent 100 mm. Data are
representative of three stained samples.significantly higher than pDCs and mo-DCs (Figure 3C).
These findings indicated that T-iPS-DCs, typical of the
mDC phenotype, were generated.
Functional Analysis of T-iPS-DCs
Since mo-DCs produced pro-inflammatory cytokines such
as TNF-a and IL-6, we checked these cytokines. Although
the levels of TNF-a and IL-6 from T-iPS-DCs were compara-
tively different from those inmo-DCswith the kindof stim-
ulations, we detected them inmature T-iPS-DCs (Figures 4A
and 4B). On another front, they, unexpectedly, did not pro-
duce IL-12p70 with any stimulations (Figure 4C).
To check the ability of phagocytosis, mature T-iPS-DCs
were treated with green-labeled zymosan. It was phagocy-
tosed by mature T-iPS-DCs (Figure 4D), and there was no
significant difference in phagocytosis properties between
T-iPS-DCs and mo-DCs obtained from the same patient(Figure 4E). These findings indicated that the ability of
phagocytosis in T-iPS-DCs was equal to that in mo-DCs.
We also examined allogeneic T cell responses, the capac-
ity to stimulate naive T cells. Mo-DCs could stimulate allo-
genic T cells even with a lower numbers of cells. Mean-
while, mature T-iPS-DCs induced a robust proliferative
response of allogeneic Tcells in proportion to the cell num-
ber, and at greater numbers (1/15 ratio of T cells), there was
no significant difference between T-iPS-DCs and mo-DCs
(Figure 4F). This implied that when evaluating the func-
tional studies of T cells using T-iPS-DCs, especially the reac-
tions of allogenic Tcells, we need to take care of the number
of T-iPS-DCs, and over a certain level, they might have the
capacity to stimulate T cells the same as mo-DCs.
Finally, we evaluated the antigen-presenting capacity of
T-iPS-DCs to autologous CD4+ T cells (Figure 4G). M3R is
known as one of the etiologic auto-antigens of SS, andStem Cell Reports j Vol. 8 j 1155–1163 j May 9, 2017 1157
Figure 2. Characterization of Differentiated T-iPS-DCs
(A–D) Flow cytometric analysis of surface molecules on (A) Sacs, (B) pre-immature cells of T-iPS-DCs, (C) immature T-iPS-DCs, and (D)
mature T-iPS-DCs. (C) and (D) were gated on CD11c+ cells.
(E) The expression levels and the proportion of CD11c+ cells. Error bars denote SD.
(F) BDCA-1 and BDCA-3 on mature iPS-DCs. *p < 0.05 versus mature T-iPS-DCs, **p < 0.05 versus immature T-iPS-DCs by Kruskal-Wallis test.
N = 3 independent experiments. The dotted line represents the isotype control.
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Figure 3. Gene Expression Analysis of
T-iPS-DCs
(A and B) qPCR analysis in Sacs, pre-imma-
ture cells of T-iPS-DCs (Pre), immature T-
iPS-DCs (Immature), mature T-iPS-DCs
(Mature), mature monocytes-derived DCs
(mo-DC), and plasmacytoid DCs (pDCs). Data
were normalized to the reference gene,
GAPDH. Values are means ± SD. *p < 0.05
versus mature T-iPS-DCs, **p < 0.05 versus
mo-DCs, ***p < 0.05 versus immature T-iPS-
DCs by Kruskal-Wallis test.
(C) qPCR analysis of CLEC9A. *p < 0.05 by
Mann-Whitney’s test. N = 3 independent
experiments.
Error bars denote SD.the important role of the autoimmune response against
M3R has been clarified (Naito et al., 2006; Iizuka et al.,
2010). M3R reactive CD4+ T cells were detected in PBMCs
of patients with SS, and the proportion of these cells was
significantly higher than in HLA-DRB1-matched healthy
donors (Figure S4B). Thus, we checked IFN-g production
from M3R reactive CD4+ T cell lines under M3R peptide
stimulation using T-iPS-DCs. A significantly higher level
of IFN-g was produced when cultured with M3R antigens,the same as mo-DCs. These results indicated that T-iPS-
DCs were able to process antigens.
The Analyses of T Cell Function in SS Using T-iPS-DCs
Although T cells from patients with systemic lupus erythe-
matosus (SLE) were reported to be poorer responders to
allogenicnon-Tcells (Russell et al., 1983), the response inpa-
tients with SS remains unknown. Thus, we evaluated the
response of allogenic Tcells, using T-iPS-DCs. As for patientsStem Cell Reports j Vol. 8 j 1155–1163 j May 9, 2017 1159
Figure 4. Functional Analysis of T-iPS-DCs
(A–C) Production of (A) TNF-a, (B) IL-6, and (C) IL-12p70 in mature T-iPS-DCs and mo-DCs stimulated for 72 hr with
TNF-a, lipopolysaccharide, and IL-4 or OK432 (10 mg/mL, 25 mg/mL) or CD40L (100 ng/mL, 1 mg/mL). Values are means ± SD. *p < 0.05 by
Mann-Whitney test.
(D) Flow cytometric analysis of CD11c gated T-iPS-DCs incubated with green-labeled zymosan for 60 min at 37C (solid line) or 4C (dotted
line).
(E) Index mean value of the ratio of zymosan incorporation at 37C and 4C. Values are means ± SD. N.S., not significant.
(F) T-iPS-DCs or mo-DCs were co-cultured with allogeneic T cells for 5 days. Proliferation of T cells was measured based on bromodeox-
yuridine uptake in the last 20 hr of the culture. *p < 0.05 by Mann-Whitney’s test. Data were run in triplicate.
(legend continued on next page)
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with SS, not only proliferation but also activation, such as
IFN-g production, of allogenic T cells had a propensity to
be lower than in healthy donors (Figures 4H and S4C).
Moreover, we tried to detect M3R-reactive CD4+ T cells.
As expected, we were able to detect M3R-reactive T cells us-
ing T-iPS-DCs, and they were comparable with mo-DCs
(Figures 4I and S4B).
These results indicate that, using T-iPS-DCs, we can
analyze some of the T cell functions of SS, which could
elucidate the steps in its pathology.DISCUSSION
The results indicate that T-iPSCs were developed from a
single CD4+ T cell from a patient with SS, through the
establishment of CD4+ T cell clones, and were differenti-
ated into an adequate amount of functional DCs via
TiPS-Sacs.
First, we established CD4+ T cell clones from PBMCs of a
patient with SS. Although various Tcell clones have been es-
tablished fromother autoimmunediseases (Greidinger et al.,
2004), as far as we know, there are only a few reports on the
development of CD4+ T cell clones from SS. SS is character-
ized by the appearance of lymphopenic conditions and a
decrease in T cell response to IL-2 (Goules and Tzioufas,
2016; Alcocer-Varela et al., 1984). Under these unfavorable
conditions, we were able to develop CD4+ T cell clones
smoothly. Since IFN-g-producing CD4+ T cells are thought
to be involved in the pathogenesis of SS (Singh and Cohen,
2012), we checked IFN-g production and selected clones.
When evaluating the immune responses, especially in
patients with uncommon diseases such as SS, it is critical
to acquire sufficient numbers of mature DCs periodically.
Haruta et al. (2013) developed a method to amplify mono-
cytes by lentivirus-mediated transduction of cMYC along
with BMI1. This method is easy and solid, but is dependent
on the efficiency of virus transduction. In fact, it was diffi-
cult to transduce these genes into CD14 cells from our
patient with SS efficiently (data not shown). Their develop-
ment fromESCs or iPSCs derived fromhumanfibroblasts of
healthy donors has been also reported (Choi et al., 2009;
Senju et al., 2007, 2011). In the latter case, mouse embry-
onic fibroblasts were used to maintain human iPSCs, and
feeder layers ofmouseOP9were used to induce hematopoi-(G) T-iPS-DCs or mo-DC pre-incubated with or without M3R peptide (10
cells/well). Autoreactive CD4+ T cell responses were evaluated. *p <
(H) T-iPS-DCs or mo-DCs (5 3 103 cells/well) were co-cultured with a
patients with SS (SS1-3) for 5 days. Proliferation of T cells was meas
(I) T-iPS-DCs (1 3 104 cells/well) were pre-incubated with or withou
(1 3 105 cells/well). M3R-reactive CD4+ T cells were evaluated.
Error bars denote SD.etic cells. In our study, T-iPSCs were maintained under
feeder-free conditions, and they were transferred on
C3H10T1/2 feeder cells to generate TiPS-Sacs. Takayama
et al. (2008) found sac-like structures after human ESCs
were cultured on C3H10T1/2 cells, which containedmulti-
potent hematopoietic progenitors. Our data showed that
TiPS-Sacs also included CD34-, CD31-, and CD43-positive
cells. Unexpectedly, the slight expression of CD11c, which
is evident on both mature and precursor DCs (Diao et al.,
2006), was confirmed on TiPS-Sacs.
Under the maturation of T-iPS-DCs, we detected high
expression levels of CCL17, CCL13, and MMP12, which
were comparable with mo-DCs. They are selectively pro-
duced bymDCs, but not by pDCs, and are upregulated after
the immature state of mDCs (Penna et al., 2002; Tang and
Saltzman, 2004). PU.1, which is required for the generation
of myeloid-derived DCs, was also detected (Guerriero et al.,
2000). On the other hand, T-iPS-DCs did not express
pre-T cell receptor a, expressed with pDCs (Spits et al.,
2000). Furthermore T-iPS-DCs expressed BDCA-3 but not
BDCA-1, and in fact higher expression of CLEC9A was de-
tected (Haniffa et al., 2012). Considered together, our re-
sults indicate that T-iPS-DCs were myeloid lineage cells,
consistent with those of previous studies on the generation
of DCs from ESCs or iPSCs (Slukvin et al., 2006; Senju et al.,
2011), and differentiated into BDCA-3+ DCs.
The ability of antigen uptake in T-iPS-DCs was equal to
that of mo-DCs, but there was a slight difference in cyto-
kine production. T-iPS-DCs produced much more IL-6
and TNF-a than mo-DCs, especially when cultured with
CD40L stimulation, butmuch less with other stimulations.
T-iPS-DCs had a tendency to express CD40higher thanmo-
DCs, and also express other co-molecules such as CD80 and
CD86 less (data not shown), which might explain the dif-
ferences. Moreover, T-iPS-DCs did not produce IL-12p70
at all. As discussed above, T-iPS-DCs expressed BDCA-3,
and it was reported that BDCA-3+DCs produced very little
or no IL-12 (Jongbloed et al., 2010; Haniffa et al., 2012),
which might be one of the reasons.
There was also a slight difference in allogenic T cell stimu-
lation. Although T-iPS-DCs in a ratio of more than 1/15 to
T cells could stimulate them as well as mo-DCs, the lower
number of T-iPS-DCs (1/100 of T cells) was insufficient
compared with that of mo-DCs. One of the reasons for this
difference might be the expression levels of co-stimulatorymg/mL) were co-cultured with the M3R-reactive T cell line (53 104
0.05 by Mann-Whitney test. N = 3 independent experiments.
llogeneic T cells (3 3 104 cells/well) of healthy donors (HC1-3) or
ured.
t M3R peptide (10 mg/mL) and co-cultured with auto-CD4+ T cells
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molecules, which are known to play critical roles in T cell
activation (Orabona et al., 2004). In addition, BDCA3+
DCs were reported to stimulate allogenic T cells less than
mo-DCs, depending on the number of DCs (MacDonald
et al., 2002; Chu et al., 2012). Although further studies are
needed, these data might support the slight difference in
T cell stimulation between T-iPS-DCs and mo-DCs.
It is not difficult to prepare a large amount of T-iPS-DCs
because there are no limitations to expanding T-iPSCs.
From only one well of 80% confluent T-iPSCs (6-well plate;
9.6 cm2), we obtained about 3–53 105 cells of DCs, repeat-
edly (Figure S3B). On the other hand, about 10mL of blood
must be collected to obtain the same number of DCs from
CD14+monocytes, each time. Thus, wewere able to obtain
stable and functional DCs from only a small blood sample
from the donor.
Taking into account the functional analyses of T-iPS-DCs,
we evaluated Tcell functions of SS. As expected from the ge-
netic similarities between SLE and SS (Teruel andAlarcon-Ri-
quelme, 2016), we confirmed that Tcells from patients with
SS, like SLE, were poorer responders to allogenic non-T cells
than T cells from healthy donors (Russell et al., 1983).
Furthermore, we could evaluate M3R-reactive CD4+ T cells,
which are thought to be one of the pathogenic Tcells for SS.
The present study describes the generation of functional
DCs from T-iPSCs prepared from a single patient with SS.
T-iPS-DCs could be useful for characterization of patho-
genic T cells in autoimmune diseases such as SS and eluci-
date the pathogenicity of autoreactive T cells.EXPERIMENTAL PROCEDURES
Differentiation of T-iPS-DCs from T-iPSCs
T-iPSCs were differentiated into hematopoietic cells as previously
reported (Nishimura et al., 2013). They were first cultured in
aMEM with 20% fetal bovine serum (FBS), GM-CSF (100 ng/mL),
and M-CSF (50 ng/mL), and cultured again in RPMI-1640 medium
with 10% FBS, GM-CSF (100 ng/mL), and IL-4 (10 ng/mL) to
generate immature T-iPS-DCs. OK432 (10 mg/mL) was added to
induce mature T-iPS-DCs. This study was approved by the local
ethics committees of each participating institution and a signed
informed consent was obtained from each subject.Statistical Analysis
Data are expressed as the mean ± SD. Differences between groups
were examined using the Mann-Whitney test and Kruskal-Wallis
test. A p value <0.05 denotes the presence of a statistically signifi-
cant difference.
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